Jun 2026 (Q2 FY26) — Aug 14, 2026
PAVmed Q2 FY26 — Strategic Progress Across Core Businesses
Read the full callPAVmed (PAVM) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
PAVmed earnings: last reported Fri, 14 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 0.03 | +450.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -21278.8 | +57304.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -5.4 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$2.25 −6.64% · −$0.16
Performance −85.2% 1Y
1Y: $15.21 on 17 Oct 2025 → $2.25. High $15.26 (20 Oct 2025), low $2.25 (19 Oct 2026).
- Previous close
- $2.41
- 52-week range
- $2.25 – $15.26
- One year
- −85.26%
Overview
- Symbol
- PAVM
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
PAVmed earnings calls (PAVM)
Financials
What the filings say
Net profit, year on year: +55% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 13 | 5 | 5 | 5 | 5 | 7 | 8 | 7 |
| Operating profit | -12 | -5 | -5 | -5 | -5 | -7 | -8 | -7 |
| Operating margin | −1157.8% | — | −68075.0% | −78583.3% | −96880.0% | −13078.9% | −36522.7% | −21278.8% |
| Other income | 72 | 6 | 24 | -8 | -1 | 4 | 7 | 0 |
| Interest | — | — | 0 | 0 | — | -0 | 0 | 0 |
| Profit before tax | 61 | 1 | 19 | -12 | -6 | -3 | -1 | -7 |
| Tax rate | — | — | 0.0% | 0.0% | — | — | 0.0% | 0.0% |
| Net profit | 64 | 1 | 19 | -12 | -5 | -1 | -0 | -5 |
| EPS ($ per share) | 6.43 | — | 38.26 | -22.08 | -0.29 | — | -4.42 | -0.87 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -37 | -54 | -88 | -139 | -228 | -294 | -255 | -259 |
| Total liabilities | 11 | 12 | 20 | 8 | 43 | 57 | 38 | 17 |
| Fixed assets | 0 | — | 0 | 2 | 2 | 2 | 0 | 0 |
| Total assets | 8 | 7 | 20 | 87 | 54 | 33 | 31 | 39 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -9 | -13 | -22 | -41 | -71 | -52 | -34 | -5 |
| Cash from investing | -0 | -0 | -0 | -4 | -5 | 1 | -16 | -0 |
| Cash from financing | 16 | 11 | 33 | 104 | 38 | 31 | 31 | 6 |
| Net cash flow | 7 | -2 | 11 | 60 | -38 | -20 | -18 | 0 |
| Capital expenditure | -0 | -0 | -0 | -1 | -2 | -0 | -0 | -0 |
| Free cash flow | -9 | -13 | -22 | -42 | -73 | -52 | -34 | -5 |
Insider filings
10 filings, all on Apr 2, 2026.
Open market
decisions to buy or sellNobody bought or sold PAVM on the open market in this window. The filings below are 10 awards.
Compensation
not trading decisions- 10
- Award — granted as compensation
Latest filings (19)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Apr 2, 2026 | Lee Victoria Tou-ho Chief Medical Officer | Award | 70,000 | $0 |
| Apr 2, 2026 | O'Neil Shaun Chief Operating Officer | Award | 110,000 | $0 |
| Apr 2, 2026 | Gordon Michael Adam General Counsel | Award | 110,000 | $0 |
| Apr 2, 2026 | Agrawal Sundeep Director | Award | 13,930 | $0 |
| Apr 2, 2026 | Sparks Ronald M Director | Award | 13,930 | $0 |
| Apr 2, 2026 | White Debra Director | Award | 13,930 | $0 |
| Apr 2, 2026 | Baxter Timothy E Director | Award | 13,930 | $0 |
| Apr 2, 2026 | Glennon Michael J Director | Award | 13,930 | $0 |
| Apr 2, 2026 | MCGRATH DENNIS M President and CFO | Award | 180,000 | $0 |
| Apr 2, 2026 | Aklog Lishan Chairman and CEO | Award | 350,000 | $0 |
| Sep 30, 2025 | O'Neil Shaun Chief Operating Officer | Award | 150,000 | $0 |
| Sep 30, 2025 | Aklog Lishan Chairman and CEO | Award | 150,000 | $0 |
| Sep 30, 2025 | MCGRATH DENNIS M President and CFO | Award | 150,000 | $0 |
| Sep 30, 2025 | Gordon Michael Adam General Counsel | Award | 150,000 | $0 |
| Sep 30, 2025 | Agrawal Sundeep Director | Award | 150,000 | $0 |
| Sep 30, 2025 | Glennon Michael J Director | Award | 150,000 | $0 |
| Sep 30, 2025 | Baxter Timothy E Director | Award | 150,000 | $0 |
| Sep 30, 2025 | White Debra Director | Award | 150,000 | $0 |
| Sep 30, 2025 | Sparks Ronald M Director | Award | 150,000 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for PAVmed Inc.
Free account. Everything above stays public.
Write why you follow PAVmed Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading